Physicochemical Properties
| Molecular Formula | C25H28FFEN3O2 |
| Molecular Weight | 477.35 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | HDAC6 38.2 nM (IC50) |
| ln Vitro | Compound II-5, also known as HDAC6-IN-15, exhibits strong inhibitory activity against HDAC6, with an IC50 value of 38.2 nM[1]. With IC50 values of 8.90 μM, 11.90 μM, 7.83 μM, 4.80 μM, and 4.80 μM, respectively, HDAC6-IN-15 (50 μL; 48 h) has anti-tumor action against 22RV1, MM1.S, MV4-11, JEKO-1, and 4T1 cells. 16.51 micrometers [1]. Acetylated α-tubulin accumulates in response to dose-dependent HDAC6-IN-15 (100, 200, 400, and 800 nM; 24 h) [1]. One can induce apoptosis with HDAC6-IN-15 (5, 10 μM; 24 h) [1]. The most stable compound in human plasma is HDAC6-IN-15 (4 mg/mL; 48 h) [1]. |
| Cell Assay |
Cell Proliferation Assay[1] Cell Types: 22RV1, MM1.S, MV4-11, JEKO-1 and 4T1 cells Tested Concentrations: 50 μL Incubation Duration: 48 h Experimental Results: demonstrated moderate anti-proliferative activities in all the cancer cell lines. Western Blot Analysis[1] Cell Types: JEKO-1 cells; 4T1 cells Tested Concentrations: 100, 200, 400, 800 nM; 5, 10 μM Incubation Duration: 24 h Experimental Results: Dramatically increase the levels of acetylated α-tubulin in a concentration dependent manner. Slightly increased the levels of histone H3 and H4 acetylation. Dramatically increased the ratio of acetylated α-tubulin at the concentration of 800 nM. Dramatically increased the levels of cleavage of PARP and caspase-3 in cells dose-dependently. Apoptosis Analysis[1] Cell Types: 4T1 cells Tested Concentrations: 5, 10 μM Incubation Duration: 24 h Experimental Results: Triggered apoptosis in 4T1 cells in a dose-dependent manner, in particularly undergoing early stage apoptosis upon 18 h treatment. |
| References |
[1]. Synthesis and bioactivity evaluation of ferrocene-based hydroxamic acids as selective histone deacetylase 6 inhibitors. Eur J Med Chem. 2023 Jan 15;246:115004. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0949 mL | 10.4745 mL | 20.9490 mL | |
| 5 mM | 0.4190 mL | 2.0949 mL | 4.1898 mL | |
| 10 mM | 0.2095 mL | 1.0474 mL | 2.0949 mL |